Zhaoke Ophthalmology Limited (HKG:6622)

Market Cap	1.49B
Revenue (ttm)	73.77M
Net Income (ttm)	-252.73M
Shares Out	546.14M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,291,000
Average Volume	3,819,450
Open	2.700
Previous Close	2.710
Day's Range	2.700 - 2.820
52-Week Range	1.200 - 3.630
Beta	1.22
RSI	53.43
Earnings Date	Mar 21, 2025

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 294
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6622

Financial Performance

In 2024, Zhaoke Ophthalmology's revenue was 69.32 million, an increase of 269.73% compared to the previous year's 18.75 million. Losses were -237.49 million, -38.32% less than in 2023.

Financial numbers in CNY